Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine. If you forget to wear or change a patch, put one on as soon as you can.
If it is almost time to put on your next patch, wait until then to apply a new patch and skip the one you missed. Do not apply extra patches to make up for a missed dose. Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light.
Keep from freezing. After removing a used patch, fold the patch in half with the sticky sides together. Make sure to dispose of it out of the reach of children and pets. There is a problem with information submitted for this request. Sign up for free, and stay up to date on research advancements, health tips and current health topics, like COVID, plus expertise on managing health. Error Email field is required. Error Include a valid email address.
To provide you with the most relevant and helpful information, and understand which information is beneficial, we may combine your email and website usage information with other information we have about you. If you are a Mayo Clinic patient, this could include protected health information.
The use of multiple medications with anticholinergic properties may be particularly problematic because of cumulative effects. Concomitant use of other medications that cause central nervous system CNS adverse reactions e. Inform patients not to operate motor vehicles or other dangerous machinery or participate in underwater sports until they are reasonably certain that scopolamine does not affect them adversely. Available data from observational studies and postmarketing reports with scopolamine use in human pregnancy have not identified a drug associated risk of major birth defects, miscarriage, or adverse fetal outcomes.
In animal studies, there was no evidence of adverse developmental effects with intravenous administration of scopolamine hydrobromide revealed in rats. Scopolamine hydrobromide has been shown to have a marginal embryotoxic effect in rabbits when administered by daily intravenous injection at doses producing plasma levels approximately times the level achieved in humans using a transdermal system.
Scopolamine is excreted in human milk. There are no available data on the effects of scopolamine on the breastfed infant or the effects on milk production. Antcholinergic agents may impact lactation. Newborns are particularly susceptible to the anticholinergic effects.
Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. Children, including neonates and infants, are particularly susceptible to the side effects of belladonna alkaloids like scopolamine. Reserve scopolamine use to approved indications in pediatric patients. The safety and effectiveness of transdermal scopolamine in children has not been established; the patch should not be used in children because it is not known whether this system will release an amount of scopolamine that could produce serious adverse effects in adolescents, children, infants and neonates.
Abatacept: Minor Because abatacept has been shown to potentiate the onset of respiratory infections, concomitant use of drugs that decrease mucociliary clearance should be used cautiously. Anticholinergics, such as scopolamine, have been shown to be capable of depressing the mucociliary transport system. Acetaminophen; Butalbital; Caffeine; Codeine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when codeine is used concomitantly with an anticholinergic drug.
Opiates increase the tone and decrease the propulsive contractions of the smooth muscle of the gastrointestinal tract. Prolongation of the gastrointestinal transit time may be the mechanism of the constipating effect. Acetaminophen; Caffeine; Dihydrocodeine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when dihydrocodeine is used concomitantly with an anticholinergic drug.
Acetaminophen; Caffeine; Magnesium Salicylate; Phenyltoloxamine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.
Clinicians should note that anticholinergic effects might be seen not only on GI smooth muscle, but also on bladder function, the eye, and temperature regulation. Additive drowsiness may also occur when antimuscarinics are combined with sedating antihistamines. Acetaminophen; Caffeine; Phenyltoloxamine; Salicylamide: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.
Acetaminophen; Chlorpheniramine; Dextromethorphan; Phenylephrine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Acetaminophen; Chlorpheniramine; Dextromethorphan; Pseudoephedrine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.
Acetaminophen; Chlorpheniramine; Phenylephrine; Phenyltoloxamine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Acetaminophen; Codeine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when codeine is used concomitantly with an anticholinergic drug.
Acetaminophen; Dextromethorphan; Doxylamine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.
Acetaminophen; Dextromethorphan; Phenylephrine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.
Acetaminophen; Diphenhydramine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Acetaminophen; Hydrocodone: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when hydrocodone is used concomitantly with an anticholinergic drug. Acetaminophen; Oxycodone: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when oxycodone is used concomitantly with an anticholinergic drug.
Acetaminophen; Pentazocine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when pentazocine is used concomitantly with an anticholinergic drug. Acetaminophen; Tramadol: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when tramadol is used concomitantly with an anticholinergic drug.
Aclidinium: Moderate Although aclidinium is minimally absorbed into the systemic circulation after inhalation, there is the potential for aclidinium to have additive anticholinergic effects when administered with other anticholinergics or antimuscarinics. Per the manufaturer, avoid concomitant administration of aclidinium with other anticholinergic medications, when possible. Aclidinium; Formoterol: Moderate Although aclidinium is minimally absorbed into the systemic circulation after inhalation, there is the potential for aclidinium to have additive anticholinergic effects when administered with other anticholinergics or antimuscarinics.
Acrivastine; Pseudoephedrine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Albuterol; Ipratropium: Moderate Although ipratropium is minimally absorbed into the systemic circulation after inhalation, there is the potential for additive anticholinergic effects when administered with other antimuscarinic or anticholinergic medications.
Per the manufacturer, avoid coadministration. Alfentanil: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when alfentanil is used concomitantly with an anticholinergic drug. Alosetron: Major Concomitant use of alosetron and anticholinergics, which can decrease GI motility, may seriously worsen constipation, leading to events such as GI obstuction, impaction, or paralytic ileus.
Although specific recommendations are not available from the manufacturer, it would be prudent to avoid anticholinergics in patients taking alosetron. Aluminum Hydroxide: Moderate Antacids may inhibit the oral absorption of anticholinergics. Simultaneous oral administration should be avoided when feasible; separate dosing by at least 2 hours to limit an interaction. Aluminum Hydroxide; Magnesium Carbonate: Moderate Antacids may inhibit the oral absorption of anticholinergics.
Aluminum Hydroxide; Magnesium Hydroxide: Moderate Antacids may inhibit the oral absorption of anticholinergics. Aluminum Hydroxide; Magnesium Hydroxide; Simethicone: Moderate Antacids may inhibit the oral absorption of anticholinergics. Aluminum Hydroxide; Magnesium Trisilicate: Moderate Antacids may inhibit the oral absorption of anticholinergics. Amantadine: Major Additive anticholinergic effects may be seen when scopolamine is used concomitantly with other antimuscarinics, such as amantadine.
Clinicians should note that antimuscarinic effects might be seen not only on GI smooth muscle, but also on bladder function, the eye, and temperature regulation.
Ambenonium Chloride: Major The muscarinic actions of ambenonium chloride can antagonize the antimuscarinic actions of scopolamine. Aminoglycosides: Minor Antiemetics, like scopolamine, should be used carefully with amikacin because they can mask symptoms of ototoxicity e. These agents block the histamine or acetylcholine response that causes nausea due to vestibular inner ear emetic stimuli such as motion.
Amoxapine: Moderate Depending on the specific agent, additive anticholinergic effects may be seen when amoxapine is used concomitantly with other anticholinergic agents. Additive CNS effects are also possible when these drugs are combined with amoxapine. Antacids: Moderate Antacids may inhibit the oral absorption of anticholinergics.
Anxiolytics; Sedatives; and Hypnotics: Moderate Scopolamine may cause dizziness and drowsiness. Aspirin, ASA; Butalbital; Caffeine; Codeine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when codeine is used concomitantly with an anticholinergic drug.
Aspirin, ASA; Caffeine; Dihydrocodeine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when dihydrocodeine is used concomitantly with an anticholinergic drug. Aspirin, ASA; Caffeine; Orphenadrine: Moderate Additive anticholinergic effects may be seen when scopolamine is used concomitantly with other drugs with moderate to significant anticholinergic effects including orphenadrine. Aspirin, ASA; Carisoprodol; Codeine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when codeine is used concomitantly with an anticholinergic drug.
Aspirin, ASA; Oxycodone: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when oxycodone is used concomitantly with an anticholinergic drug. Atomoxetine: Moderate Scopolamine and atomoxetine should be combined cautiously in patients with known cardiac disease.
Scopolamine may alter the heart rate; the predominant clinical effect is sinus tachycardia. An additive effect on heart rate may occur as atomoxetine may elevate heart rate as well as blood pressure. Atropine; Edrophonium: Major The muscarinic actions of edrophonium chloride can antagonize the antimuscarinic actions of scopolamine. Barbiturates: Moderate Scopolamine may cause dizziness and drowsiness.
Belladonna; Opium: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when opium is used concomitantly with an anticholinergic drug. Benzhydrocodone; Acetaminophen: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when benzhydrocodone is used concomitantly with an anticholinergic drug. Benzodiazepines: Moderate Scopolamine may cause dizziness and drowsiness. Brompheniramine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.
Brompheniramine; Carbetapentane; Phenylephrine: Moderate Drowsiness has been reported during administration of carbetapentane. An enhanced CNS depressant effect may occur when carbetapentane is combined with other CNS depressants including anticholinergics. Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.
Brompheniramine; Dextromethorphan; Guaifenesin: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Brompheniramine; Guaifenesin; Hydrocodone: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when hydrocodone is used concomitantly with an anticholinergic drug.
Brompheniramine; Hydrocodone; Pseudoephedrine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when hydrocodone is used concomitantly with an anticholinergic drug. Brompheniramine; Pseudoephedrine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Buprenorphine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when buprenorphine is used concomitantly with an anticholinergic drug.
Buprenorphine; Naloxone: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when buprenorphine is used concomitantly with an anticholinergic drug. Bupropion: Moderate Additive anticholinergic effects may be seen when scopolamine is used concomitantly with bupropion.
Additive drowsiness may occur. Bupropion; Naltrexone: Moderate Additive anticholinergic effects may be seen when scopolamine is used concomitantly with bupropion. Butorphanol: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when butorphanol is used concomitantly with an anticholinergic drug. Calcium Carbonate: Moderate Antacids may inhibit the oral absorption of antimuscarinics.
Calcium Carbonate; Magnesium Hydroxide: Moderate Antacids may inhibit the oral absorption of anticholinergics. Moderate Antacids may inhibit the oral absorption of antimuscarinics. Calcium Carbonate; Risedronate: Moderate Antacids may inhibit the oral absorption of antimuscarinics. Calcium Carbonate; Simethicone: Moderate Antacids may inhibit the oral absorption of antimuscarinics.
Cannabidiol: Moderate Monitor for excessive sedation and somnolence during coadministration of cannabidiol and scopolamine. CNS depressants can potentiate the effects of cannabidiol. Carbetapentane; Chlorpheniramine: Moderate Drowsiness has been reported during administration of carbetapentane. Carbetapentane; Chlorpheniramine; Phenylephrine: Moderate Drowsiness has been reported during administration of carbetapentane.
Carbetapentane; Diphenhydramine; Phenylephrine: Moderate Drowsiness has been reported during administration of carbetapentane. Carbetapentane; Guaifenesin: Moderate Drowsiness has been reported during administration of carbetapentane.
Carbetapentane; Guaifenesin; Phenylephrine: Moderate Drowsiness has been reported during administration of carbetapentane. Carbetapentane; Phenylephrine: Moderate Drowsiness has been reported during administration of carbetapentane. Carbetapentane; Phenylephrine; Pyrilamine: Moderate Drowsiness has been reported during administration of carbetapentane. Carbetapentane; Pseudoephedrine: Moderate Drowsiness has been reported during administration of carbetapentane.
Carbetapentane; Pyrilamine: Moderate Drowsiness has been reported during administration of carbetapentane. Carbidopa; Levodopa: Minor The doses of antimuscarinics and levodopa may need to be adjusted when the drugs are given simultaneously. Through central antimuscarinic actions, anticholinergics can potentiate the dopaminergic effects of levodopa. While some patients may benefit from this interaction, clinicians should be ready to decrease doses of levodopa if an antimuscarinic is added.
Carbidopa; Levodopa; Entacapone: Minor The doses of antimuscarinics and levodopa may need to be adjusted when the drugs are given simultaneously. Carbinoxamine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.
Carbinoxamine; Dextromethorphan; Pseudoephedrine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Carbinoxamine; Hydrocodone; Phenylephrine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when hydrocodone is used concomitantly with an anticholinergic drug. Carbinoxamine; Hydrocodone; Pseudoephedrine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when hydrocodone is used concomitantly with an anticholinergic drug.
Carbinoxamine; Phenylephrine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Carbinoxamine; Pseudoephedrine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.
Coadministration may increase the risk of anticholinergic and CNS depressant-related side effects. If concurrent use is necessary, monitor for excessive anticholinergic effects, sedation, and somnolence. Chlophedianol; Dexbrompheniramine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.
Chlophedianol; Dexchlorpheniramine; Pseudoephedrine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.
Chlorcyclizine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.
Chlorpheniramine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Chlorpheniramine; Codeine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when codeine is used concomitantly with an anticholinergic drug. Chlorpheniramine; Dextromethorphan: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.
Chlorpheniramine; Dextromethorphan; Phenylephrine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Chlorpheniramine; Dihydrocodeine; Phenylephrine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when dihydrocodeine is used concomitantly with an anticholinergic drug. Chlorpheniramine; Dihydrocodeine; Pseudoephedrine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when dihydrocodeine is used concomitantly with an anticholinergic drug.
Chlorpheniramine; Guaifenesin; Hydrocodone; Pseudoephedrine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when hydrocodone is used concomitantly with an anticholinergic drug. Chlorpheniramine; Hydrocodone: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when hydrocodone is used concomitantly with an anticholinergic drug. Chlorpheniramine; Hydrocodone; Phenylephrine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when hydrocodone is used concomitantly with an anticholinergic drug.
Chlorpheniramine; Hydrocodone; Pseudoephedrine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when hydrocodone is used concomitantly with an anticholinergic drug. Chlorpheniramine; Phenylephrine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Chlorpheniramine; Pseudoephedrine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.
Chlorpromazine: Moderate Additive anticholinergic effects may be seen when anticholinergics are used concomitantly with phenothiazines, including chlorpromazine.
Clinicians should note that antimuscarinic effects may be seen not only on GI smooth muscle, but also on bladder function, the eye, and temperature regulation. Additive drowsiness or other additive CNS effects may also occur. Cholinergic agonists: Major The muscarinic actions of drugs known as parasympathomimetics, including both direct cholinergic receptor agonists and cholinesterase inhibitors, can antagonize the antimuscarinic actions of anticholinergic drugs, and vice versa.
Cisapride: Moderate The use of drugs that decrease GI motility, such as scopolamine, may pharmacodynamically oppose the effects of cisapride. Clemastine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Clozapine: Moderate Clozapine exhibits potent anticholinergic effects.
Additive anticholinergic effects may be seen when clozapine is used concomitantly with anticholinergic agents.
Adverse effects may be seen not only on GI smooth muscle, but also on bladder function, the CNS, the eye, and temperature regulation. Additive drowsiness may also occur, depending on the anticholinergic agent used. Codeine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when codeine is used concomitantly with an anticholinergic drug.
Codeine; Guaifenesin: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when codeine is used concomitantly with an anticholinergic drug. Codeine; Phenylephrine; Promethazine: Moderate Additive anticholinergic effects may be seen when anticholinergics are used concomitantly with phenothiazines, including promethazine.
Moderate Monitor patients for signs of urinary retention or reduced gastric motility when codeine is used concomitantly with an anticholinergic drug. Codeine; Promethazine: Moderate Additive anticholinergic effects may be seen when anticholinergics are used concomitantly with phenothiazines, including promethazine. Crofelemer: Moderate Pharmacodynamic interactions between crofelemer and antimuscarinics are theoretically possible.
Crofelemer does not affect GI motility mechanisms, but does have antidiarrheal effects. Patients taking medications that decrease GI motility, such as antimuscarinics, may be at greater risk for serious complications from crofelemer, such as constipation with chronic use. Use caution and monitor GI symptoms during coadministration. Cyclizine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.
Cyclobenzaprine: Moderate Depending on the specific agent, additive anticholinergic effects may be seen when drugs with antimuscarinic properties like cyclobenzaprine are used concomitantly with other anticholinergics. Clinicians should note that additive antimuscarinic effects may be seen not only on GI smooth muscle, but also on bladder function, the CNS, the eye, and temperature regulation.
Monitor for effects such as constipation and urinary retention. Additive drowsiness may also occur, depending on the interacting agent. Cyproheptadine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.
Deutetrabenazine: Moderate Concurrent use of deutetrabenazine and drugs that can cause CNS depression, such as scopolamine, may have additive effects and worsen drowsiness or sedation. Advise patients about worsened somnolence and not to drive or perform other tasks requiring mental alertness until they know how deutetrabenazine affects them.
Dexchlorpheniramine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Dexchlorpheniramine; Dextromethorphan; Pseudoephedrine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.
Dextromethorphan; Diphenhydramine; Phenylephrine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.
Dextromethorphan; Promethazine: Moderate Additive anticholinergic effects may be seen when anticholinergics are used concomitantly with phenothiazines, including promethazine. It is also important information to carry with you in case of emergencies. Scopolamine Transdermal Patch pronounced as skoe pol' a meen. Why is this medication prescribed?
How should this medicine be used? Other uses for this medicine What special precautions should I follow? What should I do if I forget a dose? What side effects can this medication cause? What should I know about storage and disposal of this medication? Brand names Other names. To apply the patch, follow these instructions: After washing the area behind the ear, wipe the area with a clean, dry tissue to ensure that the area is dry.
Avoid placing on areas of your skin that have cuts, pain, or tenderness. Remove the patch from its protective pouch. Peel off the clear plastic protective strip and discard it.
Don't touch the exposed adhesive layer with your fingers. Place the adhesive side against the skin. After you have placed the patch behind your ear, wash your hands thoroughly with soap and water. Do not cut the patch. Ask your pharmacist or doctor for a copy of the manufacturer's information for the patient. Other uses for this medicine. What special precautions should I follow? Before using scopolamine patches, tell your doctor and pharmacist if you are allergic to scopolamine, other belladonna alkaloids, any other medications, or any of the ingredients in scopolamine patches.
Ask your doctor or pharmacist, check the package label, or check the Medication Guide for a list of the ingredients. Be sure to mention any of the following: antihistamines such as meclizine Antivert, Bonine, others ; medications for anxiety, irritable bowel disease, motion sickness, pain, Parkinson's disease, seizures or urinary problems; muscle relaxants; sedatives; sleeping pills; tranquilizers; or tricyclic antidepressants such as desipramine Norpramin , clomipramine Anafranil , imipramine Tofranil , and trimipramine Surmontil Many other medications may also interact with scopolamine patch, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
Your doctor will probably tell you not to use scopolamine patch. If you become pregnant while using scopolamine patches, call your doctor immediately.
0コメント